Monitoring Safety and Efficiency of the Preparation Amisulpride (Solian^®) in Common Clinical Practice

Česká verzia

Authors: E. Češková; J. Suchopár ¹
Authors place of work: Psychiatrická klinika LF MU a FN, Brno přednostka prof. MUDr. E. Češková, CSc. ; Infopharm a. s., Praha ¹
Published in the journal: Čes. a slov. Psychiat., 105, 2009, No. 2, pp. 53-60.
Category: Original Article

Summary

The tolerability and safety of amisulpride (f.o. Solian^®) has been followed for 3 months in 2 135 out-patients with schizophrenia. Totally 2 963 of side- effects in 1 243 treated (e.g. 58.22% of all treated) were observed. 2 437 side effects (82.24%) were evaluated as mildly severe, 499 (16.84 %) as moderately severe and 27 (0.91 %) as severe. According to expectation, the most frequently observed side-effects were fatigue and drowsiness (23.39), further insomnia (14.75 %) and anxiety (14.65% of all side-effects). On the other side few prolactin-dependent side-effects have been observed (6.40 % of all side-effects in 8.38 % of treated). The occurrence of menstrual abnormalities has been very rare, only in 3 cases (0.26% of all women into the study), which might be explained by the age of women included. There was a high dependence of side effects occurrence on concomitant medication. Whatever co-medication has increased significantly the occurrence of 4 out of 8 most frequently observed side effects, e.g. insomnia, fatigue and drowsiness, anxiety and extrapyramidal symptoms. Both positive and negative symptoms were improved during the 3-months therapy. With a mean daily dose of 476.6 ±176.49 mg a very good and good effect on negative symptoms was seen in 88.43% of treated, on positive symptoms in 88.24% of treated.

Key words:
amisulpride, adverse events, positive and negative symptoms in schizophrenia.

Zdroje

1. Capasso, R. M., Lineberry, T. W., Bostwick, J. M. et al.: Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950-2005. Schizophr. Res., 98, 2008, pp. 287-295.

2. Česková, E.: Amisulprid – nové benzamidové antipsychotikum II. generace (Souhrnné sdělení). Čes. a slov. Psychiat., 96, 2000, s. 418-415.

3. Češková, E., Kašpárek, T., Ondrušová, M.: Kombinace antipsychotik. Čes. a slov. Psychiat., 97, 2001, 6, s. 286-290.

4. Češková, E.: Kombinace antidepresiv. Remedia, 15, 2005, 6, s. 520-524.

5. Češková, E.: Deniban v léčbě dystymie. Čes. a slov. Psychiat., 103, 2007, s. 73-79.

6. Collona, L., Saleem, P., Donde-Nouvel, L., Rein, W.: Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int. Clin. Psychopharmacol., 14, 1999, pp. 1-10.

7. Coulouvrat, C., Dondey-Nouvel, L.: Safety of amisulpride (Solian): a review of 11 clinical studies. Int. Clin. Psychopharmacol., 14, 1999, pp. 209-218.

8. Davis, J. M., Chen, N., Glick, I. D.: A meta-analysis of the efficacy of second generation antipsychotics. Arch. Gen. Psychiatry, 60, 2003, pp. 553-563.

9. Hoffer, A., Hummer, M., Huber, R. et al.: Selection bias in clinical trials with antipsychotics. J. Clin. Psychopharmacol., 20, 2000, pp. 699-702.

10. Lam, R. W., Wan, D. D., Cohen, N. L., Kennedy, S. H.: Combining antidepressants for treatment-resistant depression: a review. J. Clin. Psychiatry, 63, 2002, pp. 685-693.

11. Leucht, S., Pitschel-Walz, G., Engel, R. R., Kissling, W.: Amisulpride, an unusual atypical antipsychotic: a meta-analysis of randomized controlled trials. Am. J. Psychiatry, 159, 2002, pp. 180-189.

12. Leucht, S., Barnes, T. R. E., Kissling, W. et al.: Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am. J. Psychiatry, 160, 2003, pp. 1209-1222.

13. Leucht, S.: Amisulpride, a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. Int. J. Neuropsychopharmacol., 7, 2004, suppl 1, S15-S20.

14. Lieberman, J. A., Stroup, T. S., McEvoy, J. P. et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med., 353, 2005, pp. 1209-1223.

15. Linden, M., Eich, F. X., Pyrkosch, L.: Do differences in atypical antipsychotics matter in routine practice. Medication switch from olanzapine and risperidone to amisulpride. Int. Clin. Psychopharmacol., 22, 2007, pp. 175-178.

16. Martin, S., Ljo, H., Peuskens, J. et al.: SOLIANOL Study Group: A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. Curr. Med. Res. Opin., 18, 2002, pp. 355-362.

17. Mortimer, A., Martin, S., Loo, H., Peuskens, J: SOLIANOL Study Group: A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int. Clin. Psychopharmacol., 19, 2004, pp. 63-69.

18. Peusken, J., De Hert, M., Mortimer, A.: For the SOLIANOL Study Group. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. Int. Clin. Psychopharmacol., 22, 2007, pp.145-152.

19. Piderman, V., Látalová, K.: Amisulprid – mýty a fakta. Psychiatrie pro praxi, 5, 2004, s. 24-27.

20. Rein, W., Coulouvrat, C., Dondeys-Nouvel, L.: Safety profile of amisulpride in short-and long-term use. Acta Psychiatr. Scand., 101, 2000, pp. 23-27.

21. Rettenbacher, M. A., Ebenbichler, C., Hofer, A. et al.: Early changes of plasma lipids during treatment with atypical antipsychotics. Int. Clin. Psychopharmacol., 21, 2006, pp. 369-372.

22. Sechter, D., Peuskens, J., Fleuron, O. et al.: Amisulpride s tudy group: Amisulpride versus risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology, 27, 2002, pp. 1071-1081.

23. Spine, E., Delon, J.: Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin. Pharmacol. Toxico, 100, 2007, pp. 4-22.

24. Strom, B. L., Faich, G. A., Reynolds, R. F. et al.: The Ziprasidone observational study of cardiac outocomes (ZODIAC): design and baseline subjekt characteristics. J. Clin. Psychiatry, 69, 2008, pp. 114-121.

25. Švestka, J.: Nová psychofarmaka. Amisulprid – atypický preparát ve skupině antipsychotik 2. generace. Psychiatrie, 3, 2000, s. 191-200.

26. Wetzel, H., Grunder, G., Hillert, A. et al.: Amisulpride versus flupenthixol in schizophrenia with predominantly positive symptomatology – a double-blind controlled study comparing a selective D2 like antagonist to a mixed D1/D2-like antagonist. Psychopharmacology, 137, 1998, pp. 223-232.